State of Alaska Department of Revenue Raises Holdings in Integra LifeSciences Holdings Corporation $IART

State of Alaska Department of Revenue lifted its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 51.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,276 shares of the life sciences company's stock after buying an additional 47,012 shares during the period. State of Alaska Department of Revenue owned about 0.18% of Integra LifeSciences worth $1,696,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in Integra LifeSciences by 2.5% in the 1st quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company's stock valued at $9,542,000 after purchasing an additional 10,492 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in Integra LifeSciences in the 1st quarter valued at approximately $251,000. Victory Capital Management Inc. increased its position in Integra LifeSciences by 1,067.6% during the first quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company's stock worth $3,254,000 after buying an additional 135,308 shares in the last quarter. Strs Ohio purchased a new position in Integra LifeSciences during the first quarter worth $400,000. Finally, GAMMA Investing LLC increased its position in Integra LifeSciences by 3,595.1% during the first quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock worth $5,140,000 after buying an additional 22,721 shares in the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Up 5.9%

Shares of NASDAQ IART opened at $14.80 on Friday. Integra LifeSciences Holdings Corporation has a 1 year low of $11.06 and a 1 year high of $27.13. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -2.27 and a beta of 1.21. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The stock's 50-day simple moving average is $14.19 and its 200-day simple moving average is $14.67.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. The firm had revenue of $415.61 million during the quarter, compared to analyst estimates of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.Integra LifeSciences's quarterly revenue was down .6% on a year-over-year basis. During the same period in the previous year, the company earned $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, equities analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a "sell (d)" rating on shares of Integra LifeSciences in a research report on Saturday, September 27th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average price target of $18.43.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.